2019-04-05 17:30
Notice to attend the Annual General Meeting of Infant Bacterial Therapeutics AB (publ)
Infant Bacterial Therapeutics AB (publ) will hold its Annual General Meeting on Monday, May 6, 2019 at 15.00 at Svenska Läkaresällskapet på...
2019-04-04 20:00
IBT publishes annual report for 2018
Today, Infant Bacterial Therapeutics AB (publ) publishes the Annual Report for the financial year 2018. The report is available on IBT’s website...
Infant Bacterial Therapeutics AB has today signed the first distribution agreement for IBP-9414 with Megapharm Ltd. for the Israeli market and the Palestinian...
2019-02-08 08:00
Infant Bacterial Therapeutics AB (publ) Interim Management Statement, January 1 – December 31, 2018
Message from the CEO IBT reached several significant milestones during 2018. IBT reached agreement with a CRO (Contract Research Organization) to conduct...
The Phase III study protocol is modified after IBT’s meeting with the FDA Yesterday afternoon (EST) Infant Bacterial Therapeutics had a meeting with...
2018-11-14 08:00
Infant Bacterial Therapeutics AB (publ) Interim Management Statement, January 1 – September 30, 2018
Message from the CEO The third quarter was dominated by extensive preparatory work relating to the planned phase III study, called “The Connection...
2018-10-08 11:30
Infant Bacterial Therapeutics AB (publ) announces that the Nomination Committee is appointed for the Annual General Meeting 2019
The Annual General Meeting of 2018 decided that the Nomination Committee would be appointed as follows: "The Chairman of the Board shall convene the...
2018-09-04 16:20
Infant Bacterial Therapeutics publishes prospectus in connection with the list change to Nasdaq Stockholm
On August 30, 2018, Infant Bacterial Therapeutics AB (publ) (”IBT” or the ”Company”) announced that Nasdaq Stockholm’s Listing...
2018-08-30 10:30
Infant Bacterial Therapeutics has been approved for listing on the main market of Nasdaq Stockholm
Nasdaq Stockholm’s Listing Committee has approved the admission of Infant Bacterial Therapeutics AB’s (“IBT” or the “Company”)...
2018-08-16 08:00
Infant Bacterial Therapeutics AB (publ) Interim Management Statement, January 1 – June 30, 2018
Message from the CEO The second quarter was dominated by extensive preparatory work relating to the pivotal phase III study, called “The Connection...